Literature DB >> 27277549

Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient: Feasibility of a patient-derived xenograft.

Jiyong Kwak1, Jin-Kyoung Shim2, Dong Seok Kim2, Ji-Hyun Lee2, Junjeong Choi3, Junseong Park2, Kyoung-Jin Shin4, Se-Hoon Kim5, Pilnam Kim6, Yong-Min Huh7, Eui Hyun Kim2, Jong Hee Chang2, Sun Ho Kim2, Seok-Gu Kang2.   

Abstract

The existence of tumorspheres (TSs) might confer treatment resistance to pineoblastoma (PB). The existence of PB TSs with cellular immortalization potential has not yet been reported. We developed a procedure for isolating TSs from recurrent PB (rPB) and tested whether their properties made them suitable for use as a patient-derived xenograft (PDX). Immunocytochemical staining, RT-PCR and quantitative real-time PCR showed that, among stemness proteins, CD133, musashi and podoplanin were expressed at elevated levels in rPB TSs, but nestin was not. rPB TSs cultured under neuro-glial differentiation conditions expressed TUBB3, but not GFAP, MBP or NeuN. Unlike glioblastoma TSs, rPB TSs showed no clear evidence of invasion in 3D invasion assay or increased expression of genes associated with epithelial-mesenchymal transition. An orthotopic xenograft showed that tumor xenografts replicated the histopathological features of the patient tumor and expressed similar genome profiles, as determined by short tandem repeat genotyping. These data demonstrate the isolation and the characterization of rPB TSs for the first time. Using an orthotopic xenograft, we showed that rPB TSs could replicate the patient tumor, demonstrating their potential as a PDX for precision medicine.

Entities:  

Mesh:

Year:  2016        PMID: 27277549     DOI: 10.3892/ijo.2016.3554

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.

Authors:  Junseong Park; Chang Gon Kim; Jin-Kyoung Shim; Jong Hoon Kim; Hoyoung Lee; Jae Eun Lee; Min Hwan Kim; Keeok Haam; Inkyung Jung; Su-Hyung Park; Jong Hee Chang; Eui-Cheol Shin; Seok-Gu Kang
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

2.  A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.

Authors:  Tae Hoon Roh; Ji-Hyun Lee; Seo Jin Kim; Jin-Kyoung Shim; Junseong Park; Seon-Jin Yoon; Wan-Yee Teo; Se Hoon Kim; Jong Hee Chang; Seok-Gu Kang
Journal:  J Neurooncol       Date:  2021-11-22       Impact factor: 4.130

Review 3.  Integrated cancer tissue engineering models for precision medicine.

Authors:  Michael E Bregenzer; Eric N Horst; Pooja Mehta; Caymen M Novak; Shreya Raghavan; Catherine S Snyder; Geeta Mehta
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

4.  Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.

Authors:  Seon-Jin Yoon; Hye Young Son; Jin-Kyoung Shim; Ju Hyung Moon; Eui-Hyun Kim; Jong Hee Chang; Wan Yee Teo; Se Hoon Kim; Sahng Wook Park; Yong-Min Huh; Seok-Gu Kang
Journal:  J Transl Med       Date:  2020-12-14       Impact factor: 5.531

5.  A lignan from Alnus japonica inhibits glioblastoma tumorspheres by suppression of FOXM1.

Authors:  Jin-Kyoung Shim; Seung Hoon Lim; Ji Hye Jeong; Ran Joo Choi; Yoojung Oh; Junseong Park; Sunghee Choi; Junpyo Hong; Seo Jin Kim; Ju Hyung Moon; Eui Hyun Kim; Wan-Yee Teo; Bong Jin Park; Jong Hee Chang; Jae-Ha Ryu; Seok-Gu Kang
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

6.  The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model.

Authors:  IlKyoo Koh; Junghwa Cha; Junseong Park; Junjeong Choi; Seok-Gu Kang; Pilnam Kim
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

7.  Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy.

Authors:  Deena M A Gendoo; Ronak Ghanbari-Azarnier; Philip E D Chung; Jeff C Liu; Zhe Jiang; Jennifer Tsui; Dong-Yu Wang; Xiao Xiao; Bryan Li; Adrian Dubuc; David Shih; Marc Remke; Ben Ho; Livia Garzia; Yaacov Ben-David; Seok-Gu Kang; Sidney Croul; Benjamin Haibe-Kains; Annie Huang; Michael D Taylor; Eldad Zacksenhaus
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.